Galectin Therapeutics Inc

Healthcare · Biotechnology

3.60$ +0.6% vs. previous close Closing price · As of: Oct 8, 2026

Statements

Balance Sheet

Galectin Therapeutics Inc (GALT) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 15 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size %

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet GALT
Line item	Q3 16	Q4 16	Q1 17	Q2 17	Q3 17	Q4 17	Q1 18	Q2 18	Q3 18	Q4 18	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Total Assets	16	16	14	9.3	7.0	4.2	4.9	11	11	9.0	7.8	53	51	48	44	41	34	30	23	33	38	42	34	26	18	21	20	20	22	28	26	28	29	17	9.5	16	13	20	16	15
Current Assets	16	16	14	9.3	7.0	3.8	4.7	11	11	8.8	7.5	53	50	48	44	41	34	29	23	33	38	42	34	26	17	21	20	19	22	28	25	27	29	17	9.3	15	13	19	16	15
Cash	16	15	14	9.1	7.0	3.1	4.0	10	10	8.3	7.0	52	50	47	43	41	33	27	21	32	37	40	32	24	16	19	18	18	20	26	24	26	27	15	7.4	14	12	18	14	13
Cash & Short-Term Investments	16	15	14	9.1	7.0	3.1	4.0	10	10	8.3	7.0	52	50	47	43	41	33	27	21	32	37	40	32	24	16	19	18	18	20	26	24	26	27	15	7.4	14	12	18	14	13
Inventory	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Property, Plant & Equipment	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	–	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Goodwill	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Intangible Assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Total Liabilities	4.1	3.8	4.4	3.5	4.3	3.0	2.3	1.4	1.6	2.1	1.0	1.4	1.3	2.9	1.4	4.3	2.5	5.4	4.7	16	29	39	40	41	40	53	63	71	73	88	97	110	121	121	122	133	138	146	146	152
Current Liabilities	4.1	3.8	4.4	3.5	4.3	3.0	2.3	1.4	1.6	2.1	0.9	1.3	1.2	2.8	1.3	4.3	2.5	5.4	4.7	6.1	8.3	9.0	9.5	11	9.6	13	12	10.0	11	16	13	15	25	35	111	11	136	8.0	7.3	152
Short-Term Debt	–	–	–	–	–	–	–	–	–	–	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	11	21	97	0.1	122	0.0	0.0	138
Accounts Payable	0.7	0.9	1.3	0.4	0.2	0.6	1.2	0.2	0.2	0.3	0.4	0.4	0.4	1.7	0.7	0.2	0.7	1.3	0.4	0.9	1.9	1.8	1.9	3.0	2.4	3.9	2.6	2.0	2.7	6.4	3.8	3.7	2.8	5.7	6.5	5.9	5.4	3.2	3.1	3.7
Long-Term Debt	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	–	0.1	–	–	–	–	–	–	–	–	9.6	19	29	29	30	30	40	50	60	61	72	82	93	94	85	11	120	–	134	136	–
Shareholders' Equity	12	12	9.6	5.8	2.7	1.2	2.6	9.8	9.0	6.9	6.8	52	49	46	43	37	32	24	18	17	9.2	2.6	-6.2	-15	-22	-32	-43	-51	-51	-60	-71	-82	-92	-103	-112	-117	-125	-126	-130	-137
Retained Earnings	-159	-164	-169	-174	-178	-181	-186	-190	-193	-196	-205	-208	-211	-216	-220	-226	-232	-240	-246	-255	-263	-271	-281	-290	-299	-310	-321	-330	-344	-354	-366	-378	-390	-402	-411	-419	-427	-433	-438	-447
Shares Outstanding	29	29	34	35	35	35	37	38	41	41	45	50	57	42	57	57	57	57	57	58	59	59	59	59	59	59	59	60	60	60	62	62	62	63	63	63	64	64	66	66

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Balance Sheet

Cookie settings